Transfusion-free kidney transplantation in Jehovah’s witnesses: a propensity-score matched cohort study
Frontiers in Nephrology · 03.11.2026 · 6
DOI: 10.3389/fneph.2026.1938525 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Nephrology, online erschienen am 03.11.2026. Verfasst von Betty Chamoun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospital del Mar, Barcelona, Spain. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Jehovah’s Witnesses (JWs) refuse blood transfusions on religious grounds, creating a major challenge in kidney transplantation (KT), where perioperative bleeding may necessitate transfusion support. Evidence regarding transfusion-free KT in JWs remains limited. We evaluated the feasibility and early clinical outcomes of a transfusion-free KT protocol in JW patients.
Methods
We performed a single-centre propensity score–matched cohort study including all JW recipients who underwent KT under a transfusion-free protocol between 2016 and 2025. The protocol included pre-transplant haemoglobin optimisation to ≥13 g/dL. JW recipients were matched 1:3 to non-JW controls based on recipient age and sex, donor type, and transplant date. Outcomes included peri-transplant transfusion, anaemia management, bleeding-related complications, and early post-transplant results.
Results
27 JW recipients and 74 controls were included. Peri-transplant transfusion was completely avoided in JW recipients (0/27), whereas 24/74 controls (32.4%) required transfusion support. Bleeding-related complications occurred in 14.8% of JW recipients and 11.3% of controls (RR 1.65, 95% CI 0.44–6.21). Admission haemoglobin was higher in JW recipients (14.2 vs 11.5 g/dL; MD 2.69, 95% CI 2.15–3.22), as was nadir haemoglobin (10.0 vs 8.5 g/dL; MD 1.50, 95% CI 0.55–2.45). However, the absolute decrease from admission to nadir was greater in JW recipients (4.14 vs 3.01 g/dL; MD 1.13, 95% CI 0.21–2.06). Hospital stay was longer in JW recipients (MD 5.2 days, 95% CI −0.10 to 10.31).
Conclusions
A transfusion-free KT protocol was feasible in JW recipients managed at an experienced centre and enabled complete avoidance of peri-transplant transfusion. Early outcomes are reported descriptively and should be interpreted with caution because of the small sample size and residual imbalance between groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Hospital del Mar, Barcelona, Spain.
- Hospital del Mar Research Institute, Barcelona, Spain.
- Faculty of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
- Urology Department, Hospital del Mar, Barcelona, Spain.
- Anesthesiology Department, Hospital del Mar, Barcelona, Spain.
- Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Zitieren
APA
Chamoun, B., Jiménez De Parga, A., Juez, A., Burballa, C., Buxeda, A., Cidraque, I., Redondo Pachón, D., Frances, A., Cecchini, L., Carazo, J., Pascual, J., Crespo, M., & Pérez Sáez, M. J. (2026). Transfusion-free kidney transplantation in Jehovah’s witnesses: a propensity-score matched cohort study. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1938525
Vancouver
Chamoun B, Jiménez De Parga A, Juez A, Burballa C, Buxeda A, Cidraque I, et al. Transfusion-free kidney transplantation in Jehovah’s witnesses: a propensity-score matched cohort study. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1938525
BibTeX
@article{Chamoun2026,
author = {Chamoun, Betty and Jiménez De Parga, Alexia and Juez, Almudena and Burballa, Carla and Buxeda, Anna and Cidraque, Ignacio and Redondo Pachón, Dolores and Frances, Albert and Cecchini, Lluis and Carazo, Jesús and Pascual, Julio and Crespo, Marta and Pérez Sáez, María José},
title = {Transfusion-free kidney transplantation in Jehovah’s witnesses: a propensity-score matched cohort study},
journal = {Frontiers in Nephrology},
year = {2026},
volume = {6},
doi = {10.3389/fneph.2026.1938525}
}
EUVIMED